Abstract
Extracellular vesicles (EVs) enable cell-to-cell communication and, by delivering antigens, can stimulate the immune response strongly. Approved in use SARS-CoV-2 vaccine, candidates immunize with the viral spike protein delivered via viral vectors, translated by injected mRNAs, or as a pure protein. Here, we outline a novel methodological approach for generating SARS-CoV-2 vaccine using exosome that delivers antigens from the SARS-CoV-2 structural proteins. Engineered EVs can be loaded with viral antigens, thus acting as antigens presenting EVs, eliciting strong and targeted CD8(+) T cell and B cell, offering a unique approach to vaccine development. Engineered EVs thus portray a safe, adaptable, and effective approach for a virus-free vaccine development.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Ji Y, Ma Z, Peppelenbosch MP, Pan Q (2020) Potential association between COVID-19 mortality and health-care resource availability. Lancet Glob Health 8:e480
Thery C, Witwer KW, Aikawa E et al (2018) Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles 7:1535750
Lee Y, El Andaloussi S, Wood MJ (2012) Exosomes and microvesicles: extracellular vesicles for genetic information transfer and gene therapy. Hum Mol Genet 21:R125–R134
Lou G, Chen Z, Zheng M, Liu Y (2017) Mesenchymal stem cell-derived exosomes as a new therapeutic strategy for liver diseases. Exp Mol Med 49:e346
Walker S, Busatto S, Pham A et al (2019) Extracellular vesicle-based drug delivery systems for cancer treatment. Theranostics 9:8001–8017
Jafari D, Shajari S, Jafari R et al (2020) Designer exosomes: a new platform for biotechnology therapeutics. BioDrugs 34:567–586
Colao IL, Corteling R, Bracewell D, Wall I (2018) Manufacturing exosomes: a promising therapeutic platform. Trends Mol Med 24:242–256
Morel PA, Falkner D, Plowey J, Larregina AT, Falo LD (2004) DNA immunisation: altering the cellular localisation of expressed protein and the immunisation route allows manipulation of the immune response. Vaccine 22:447–456
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Kim, J., Thapa, N. (2023). Exosome-Based COVID-19 Vaccine. In: Vainio, S. (eds) Cell-Secreted Vesicles. Methods in Molecular Biology, vol 2668. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-3203-1_20
Download citation
DOI: https://doi.org/10.1007/978-1-0716-3203-1_20
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-3202-4
Online ISBN: 978-1-0716-3203-1
eBook Packages: Springer Protocols